Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... AACC, a global scientific and medical professional ... an updated brand identity today that reflects the organization,s ... healthcare environment and continue to do what they do ... the care they need. " The ... essential role in saving lives and making people healthier," ...
(Date:8/1/2014)... 2014 Once a decision has been ... webinar will discuss how to define your tolerance for ... Bob Allen, Senior Director of Facilities Integration at Fluor ... Fluor Industrial Services, and special guest Carrier Li, Director ... Amgen, as they provide an examination of the Conceptual ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... Alan Turing, the British mathematician (1912-1954), is famous for ... the 20th century. In 1936 he published a paper, ... first formal concept of a computer algorithm. He next ... designing the machines which cracked the German military codes, ... crucial battles. And in the late 1940,s he turned ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3
... awards recognize outstanding journalism demonstrating the essential role ... , , ... 16 The Foundation for Biomedical Research (FBR) today announces the ... named in honor of FBR,s late chairman Dr. Michael E. DeBakey ...
... , AKRON, Ohio , June 16 On Wednesday, ... Ohio promises to inspire renewed hope for new jobs in ... coatings industries will share their insight on innovation, global commerce and the new ... at www.ohio.com/jobgrowth . , , ...
... and SAN DIEGO , June 16 ... Biosciences, Inc. (Nasdaq: NBIX ) today announced that ... and commercialize elagolix for the treatment of endometriosis-related pain. ... antagonist, which has recently completed a phase IIb study ...
Cached Biology Technology:2010 Michael E. DeBakey Journalism Awards Announced 2Free Web Cast On Fueling Ohio's New Job Growth 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 3Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 4Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 5
(Date:8/1/2014)... USA One of the most diverse families in ... Lucinidae (or lucinids) -- originated more than 400 million ... life habits like those of its modern members. This ... University of Hawaii, published online on 25 July 2014, ... significant symbiotic relationships. , At is origin, the Lucinidae ...
(Date:8/1/2014)... a more effective way to control the condition, thanks ... National University of Singapore (NUS). , The team, led ... Pharmacology at the NUS Yong Loo Lin School of ... PhD graduate from the Saw Swee Hock School of ... herbal-based anti-malarial drug, can be used to control asthma, ...
(Date:8/1/2014)... study, including two Simon Fraser University research associates, ... policymakers must collaborate closely on minimizing damage to ... Popescu and Maureen Ryan, David H. Smith Conservation ... among eight international co-authors of the newly published ... Environment . , Shale gas development is the ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3
... where and how some plant seeds store iron, a valuable ... plants. Their research helps address the worldwide problem of iron ... iron is stored in the developing vascular system of the ... particular, iron is stored in the vacuole, a plant cell's ...
... evaluated improvements in the end-of-life care in intensive care ... special supplement to Critical Care Medicine, the journal of ... dedicated entirely to end-of-life care in the critical care ... critically ill and dying patients in the ICU remains ...
... factor known to be important for the survival of ... motor neurons ?critical brain cells that connect the cerebral ... motor neuron diseases like amyotrophic lateral sclerosis (ALS or ... of Nature Neuroscience, two investigators from Massachusetts General Hospital ...
Cached Biology News:Plant studies reveal how, where seeds store iron 2End-of-life care can be improved 2End-of-life care can be improved 3Growth factor stimulates rapid extension of key motor neurons in brain 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Immunogen: Goats were immunized ... Antibody was isolated by affinity chromatography using ... anti- human T7 affinity purified antibodies were ... method. Specificity: Antibody ...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Biology Products: